Literature DB >> 23588561

Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations.

Carmen C Franz1, Carole Hildbrand, Christa Born, Sabin Egger, Alexandra E Rätz Bravo, Stephan Krähenbühl.   

Abstract

AIM AND
BACKGROUND: To assess drug-related problems in patients with liver cirrhosis by investigating the prevalence of inadequately dosed drugs and their association with adverse drug reactions (ADRs) and hospitalizations.
METHODS: This was a cross-sectional retrospective study assessing the dose adequacy of drug treatment of 400 cirrhotic patients at hospital admission based on the authors' own previous studies and standard literature. The prevalence of total and preventable ADRs and of hospitalizations due to preventable ADRs was determined.
RESULTS: Of all 1653 drugs prescribed (median 4 per patient), 336 (20 %) drugs were inadequately dosed in 184 patients. Overall, 210 ADRs (78 % preventable) occurred in 120 patients. Sixty-nine ADRs (33 % of all ADRs) were associated with inadequate drug dosing in 46 patients, of which 68 % were preventable. Nonsteroidal anti-inflammatory drugs and psycholeptics in particular frequently caused preventable ADRs associated with inadequate drug dosing. Inadequate drug dosing was more frequently associated with ADRs than adequate drug dosing, and patients receiving inadequately dosed drugs were more frequently admitted to the hospital due to ADRs. Hospitalization of patients receiving inadequately dosed drugs that caused preventable ADRs resulted in 94 additional hospital days.
CONCLUSION: In this retrospective study, inadequate drug dosing was associated with an increased frequency of ADRs, hospital admissions and hospital days in cirrhotic patients. We therefore conclude that the careful dosing of critical drugs is important in patients with liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588561     DOI: 10.1007/s00228-013-1502-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

Review 1.  The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance.

Authors:  David G Le Couteur; Robin Fraser; Sarah Hilmer; Laurent P Rivory; Allan J McLean
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Outpatient management of cirrhosis: a narrative review.

Authors:  Ronnie E Mathews; Brendan M McGuire; Carlos A Estrada
Journal:  South Med J       Date:  2006-06       Impact factor: 0.954

Review 3.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis.

Authors:  T M Bauer; B Steinbrückner; F E Brinkmann; A K Ditzen; H Schwacha; J J Aponte; K Pelz; M Kist; H E Blum
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

5.  Liver disease selectively modulates cytochrome P450--mediated metabolism.

Authors:  Reginald F Frye; Nathalie K Zgheib; Gary R Matzke; Diego Chaves-Gnecco; Mordechai Rabinovitz; Obaid S Shaikh; Robert A Branch
Journal:  Clin Pharmacol Ther       Date:  2006-09       Impact factor: 6.875

Review 6.  Drug-related problems in hospitals: a review of the recent literature.

Authors:  Anita Krähenbühl-Melcher; Raymond Schlienger; Markus Lampert; Manuel Haschke; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective.

Authors:  Jasmohan S Bajaj; Ashwin N Ananthakrishnan; Muhammad Hafeezullah; Yelena Zadvornova; Alexis Dye; Emily L McGinley; Kia Saeian; Douglas Heuman; Arun J Sanyal; Raymond G Hoffmann
Journal:  Am J Gastroenterol       Date:  2009-10-20       Impact factor: 10.864

Review 8.  Pharmacotherapy of ascites associated with cirrhosis.

Authors:  P Ginès; V Arrovo; J Rodés
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

9.  Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis.

Authors:  A J MacGilchrist; G G Birnie; A Cook; G Scobie; T Murray; G Watkinson; M J Brodie
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

10.  Evidence for altered hepatic gluconeogenesis in patients with cirrhosis using in vivo 31-phosphorus magnetic resonance spectroscopy.

Authors:  K K Changani; R Jalan; I J Cox; M Ala-Korpela; K Bhakoo; S D Taylor-Robinson; J D Bell
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

View more
  10 in total

1.  A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.

Authors:  Julie Steelandt; Elodie Jean-Bart; Sylvain Goutelle; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

2.  Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies.

Authors:  Ejaz Cheema; Aliaa Al-Aryan; Abdullah Al-Hamid
Journal:  Eur J Clin Pharmacol       Date:  2019-05-11       Impact factor: 2.953

3.  Screening for impaired liver function as a risk factor for drug safety at hospital admission of surgical patients.

Authors:  Dorothea Strobach; Angelika Poppele; Hanna Mannell; Monika Andraschko; Susanne Schiek; Thilo Bertsche
Journal:  Int J Clin Pharm       Date:  2019-12-05

4.  Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.

Authors:  Urs Duthaler; Fabio Bachmann; Claudia Suenderhauf; Tanja Grandinetti; Florian Pfefferkorn; Manuel Haschke; Petr Hruz; Jamal Bouitbir; Stephan Krähenbühl
Journal:  Clin Pharmacokinet       Date:  2022-05-16       Impact factor: 5.577

5.  A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls.

Authors:  Anne B Taegtmeyer; Manuel Haschke; Lydia Tchambaz; Mirabel Buylaert; Martin Tschöpl; Ulrich Beuers; Jürgen Drewe; Stephan Krähenbühl
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

Review 6.  Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.

Authors:  Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; Nicole G M Hunfeld; Minke Kranenborg; Margje H Monster-Simons; Sandra A W van Putten; Herold J Metselaar; Katja Taxis; Sander D Borgsteede
Journal:  BMJ Open       Date:  2016-10-12       Impact factor: 2.692

7.  Safe use of proton pump inhibitors in patients with cirrhosis.

Authors:  Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; S Froukje Harkes-Idzinga; Nicole G M Hunfeld; Herold J Metselaar; Margje H Monster-Simons; Sandra A W van Putten; Katja Taxis; Sander D Borgsteede
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

8.  Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment.

Authors:  Rianne A Weersink; Lotte Timmermans; Margje H Monster-Simons; Peter G M Mol; Herold J Metselaar; Sander D Borgsteede; Katja Taxis
Journal:  Front Pharmacol       Date:  2019-09-17       Impact factor: 5.810

Review 9.  Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.

Authors:  Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; S Froukje Harkes-Idzinga; Nicole G M Hunfeld; Herold J Metselaar; Margje H Monster-Simons; Katja Taxis; Sander D Borgsteede
Journal:  Drug Saf       Date:  2018-06       Impact factor: 5.606

10.  Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study.

Authors:  Rianne A Weersink; Katja Taxis; Joost P H Drenth; Eline Houben; Herold J Metselaar; Sander D Borgsteede
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.